FDA grants accelerated approval to Forzinity for Barth syndrome

Stealth BioTherapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Forzinity (elamipretide HCl), marking it as the first approved therapy for Barth syndrome. This ultra-rare genetic mitochondrial disorder primarily affects males and is characterized by severe heart failure, muscle weakness, and fatigue. The condition often leads to premature […] The post FDA grants accelerated approval to Forzinity for Barth syndrome appeared first on Longevity.Technology.